ChinaBio Today -- The caliber of the management team is a key consideration when deciding which pharmaceutical company to invest in, venture capitalists said at an industry forum held in Shanghai on July 7 and July 8. In recent years, China’s pharmaceutical industry has emerged to become one of the biggest targets for both domestic and foreign venture capitalists, who are now a little more investment savvy. “Whenever we look at a pharmaceutical company, we always pay close attention to the management team first,” said Kevin Li, partner at HBM BioMed China Ltd., at the ChinaBio® Investor Forum 2008 [in Shanghai]. More details...
